Trial site
Hackensack
Hackensack, New Jersey, United StatesNot linked to an institution yet
- 22running trials
- 5closed trials
- 0trials confirmed by the site in the last 60 days
- –languages not stated
The site has not confirmed any trial yet.
Running trials
Recruiting
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
NCT07681596· Phase 1/2· Source
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281· Phase 3· Source
Not yet recruiting
LTFU for All Cell and Gene Therapy Studies
NCT06194461· Source
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803· Phase 3· Source
Recruiting
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
NCT06795022· Phase 1/2· Source
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112· Phase 3· Source
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038· Phase 1/2· Source
Recruiting
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
NCT06542250· Phase 1/2· Source
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595· Phase 3· Source
Recruiting
Study of AZD0754 in Participants With Metastatic Prostate Cancer
NCT06267729· Phase 1/2· Source
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864· Phase 3· Source
Active, not recruiting
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
NCT06084884· Phase 1/2· Source
Active, not recruiting
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
NCT05951959· Phase 2· Source
Recruiting
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861· Phase 3· Source
Active, not recruiting
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577· Phase 3· Source
Active, not recruiting
Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04612751· Phase 1· Source
Active, not recruiting
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
NCT04421963· Phase 3· Source
Active, not recruiting
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
NCT02972840· Phase 3· Source
Active, not recruiting
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
NCT02717624· Phase 1· Source
Active, not recruiting
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
NCT02477696· Phase 3· Source
Active, not recruiting
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
NCT02475681· Phase 3· Source
Active, not recruiting
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
NCT02213926· Phase 2· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Researchers
No researcher is linked here yet.
Report an error